Last checked at 17 Jul 2013 16:34
17th July, 2013
BEXIMCO PHARMACEUTICALS LTD.
Share Dividend issued and Total Voting Rights
Beximco Pharmaceuticals Limited ("BPL" or "Company"; AIM Symbol: BXP) announces that the stock dividend proposed on 16 May 2013 and passed by shareholders at the Annual General Meeting on 29 June 2013 has been credited to shareholder accounts.
The Company has applied for admission of 10,247,025 new GDRs issued in respect of the stock dividend to be admitted to trading on the London Stock Exchange's AIM market and admission is expected to occur on or around 23 July 2013.
Following issuance of the stock dividend, the total issued share capital of the Company will be 350,334,907 ordinary shares of Taka 10 ("Ordinary Shares"), of which 78,560,526 will be represented by GDRs, each representing one Ordinary Share of Taka 10. The new Ordinary Shares will rank pari passu in all respects with the existing issued Ordinary Shares, all having voting rights.
Shareholders in the Company may use the number of 350,334,907 Ordinary Shares to calculate their reporting obligations under DTR 5.
For further information please visit www.beximco-pharma.com or enquire to:
Beximco Pharma
Nazmul Hassan MP, Managing Director
Tel: +880 2 861 9151, ext.20080
Md. Asad Ullah, FCS, Executive Director & Company Secretary
Tel; +880 2 8618220-1, Ext 10140
Libertas Capital Corporate Finance (Nomad)
Thilo Hoffmann
Tel: +44 (0)20 7569 9650
Daniel Stewart & Company (Broker)
Paul Shackleton
James Thomas
Tel: +44 (0)20 7776 6550
FTI Consulting
Simon Conway / Susan Stuart / Victoria Foster-Mitchell
Tel: +44 (0)20 7269 7169
Notes to Editors
About Beximco Pharmaceuticals Limited
Founded in 1976 and based in Dhaka, Bangladesh, Beximco Pharma manufactures and sells generic pharmaceutical formulation products and active pharmaceutical ingredients. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies. The Company operates from a 23 acre site in Dhaka and has manufacturing facilities for producing various drugs in different delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, prefilled syringes, injectables, nebulizer solutions etc. Ensuring access to quality medicines is the powerful aspiration that motivates 2,700 employees of the Company.
Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of Australia, European Union, Gulf nations, and Brazil, among others. The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in Africa, including Mauritius, Kenya, Ghana and Nigeria, Pacific Island and Latin & Central American countries, Middle East and South East Asia, including Singapore, Malaysia, Philippines and Hong Kong.
.